GlobeNewswire Inc.··NaBiogen's Lupus Drug Shows Promise Again, Edges Closer to Historic FDA Approval
Biogen announces second positive Phase 2 trial of litifilimab for cutaneous lupus, showing 11.8% greater disease reduction than placebo, advancing toward potential first targeted CLE therapy in 70 years.
BIIBFDA Breakthrough Therapy Designationclinical trial results